Alumis Inc. (ALMS) · Sep 1, 2026 · Other events

Alumis lupus trial misses endpoints as IFNGS-high subgroup offers a rescue path

Below the bar — Overall BICLA: 40.0–42.2% vs 35.7% placebo; p=0.35–0.50

Alumis’ LUMUS lupus study failed its overall endpoints, but responses in IFNGS-high patients support a biomarker-defined Phase 3 strategy.

The overall trial failed its core test. LUMUS did not meet its primary BICLA endpoint or key secondary endpoints in the full SLE population. 〔0〕 The placebo-adjusted BICLA differences were small and statistically inconclusive across all doses, while SRI-4 produced only one nominally significant dose response. That puts the study below the bar for an unselected Phase 3 program.

Endpoint at Week 48Placebo20mg QD20mg BID40mg BID
BICLA response35.7%40.0%42.2%41.0%
BICLA delta vs. placebo—+4.7 pts+6.9 pts+6.2 pts
BICLA p-value—0.50180.34550.3740
SRI-4 response40.4%60.9%52.1%52.7%
SRI-4 delta vs. placebo—+20.9 pts+12.3 pts+13.9 pts
SRI-4 p-value—0.00280.09090.0417

The company’s explanation is plausible but does not erase the miss. Forty percent of enrolled patients were IFNGS-low, a group Alumis says is less responsive to interferon-pathway treatment and more prone to placebo response. 〔1〕 That result shifts the development question from “does the drug work broadly in SLE?” to “can a biomarker-defined subgroup support a viable indication?”

The IFNGS-high subgroup provides a credible rescue signal, but it is not the headline result. In the prespecified IFNGS-high subgroup, BICLA response was 40.7%–52.6% on envudeucitinib versus 28.6% on placebo, and SRI-4 response was 57.8%–67.7% versus 33.1%. 〔2〕 The consistency across endpoints and doses supports further testing, but the subgroup analysis cannot fully substitute for the failed overall population result, particularly because the next trial would need narrower enrollment and a validated biomarker strategy.

Safety is a supporting positive, not a counterweight to the efficacy miss. The company reported generally good tolerability and no new safety signals. 〔3〕 Alumis plans FDA and EMA end-of-Phase-2 meetings to refine Phase 3 design, dose, enrollment criteria, and biomarker selection. 〔4〕 Net: the lupus opportunity is materially narrowed from a broad SLE thesis to a higher-risk, biomarker-selected development path.

What to watch next

End-of-Phase-2 meetings with FDA and EMA

Original filing on SEC EDGAR

More Alumis Inc. news

Alumis lupus trial misses endpoints as IFNGS-high subgroup offers a rescue path | ALMS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.